96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

171 trials found

diseases per page:

Showing 1 to 10 of 171 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05242458 (ClinicalTrials.gov)	March 2, 2022	15/2/2022	A Study of Ustekinumab Treatment in Children With Crohn's Disease	Real-world Evidence for the Effectiveness and Safety of UstekinumabTreatment in Children With Crohn' ...	Crohn's Disease	Drug: Ustekinumab	Janssen Research & Development, LLC	ImproveCareNow (ICN);Children's Hospital Medical Center, Cincinnati	Not yet recruiting	2 Years	25 Years	All	662		United States
2	NCT04779762 (ClinicalTrials.gov)	January 2022	28/2/2021	Stelara and Diet Trial for Crohns Disease	Stelara and CDED Diet Trial for Crohns Disease	Crohn Disease	Other: Crohn's disease exclusion diet (CDED);Drug: Ustekinumab Injection [Stelara]	Wolfson Medical Center	Sheba Medical Center, Israel	Not yet recruiting	18 Years	65 Years	All	40	N/A	Israel
3	EUCTR2020-004527-16-IT (EUCTR)	21/12/2021	29/09/2021	A study to test whether BI 706321 combined with ustekinumab helps people with Crohn’s Disease	A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, ph ...	Crohn`s Disease (CD) MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disea ...	Trade Name: Stelara 130mg / 26mL concentrate for solution for infusion Product Name: Stelara 130mg / 26m ...	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	France;United States;Czechia;Spain;Poland;Belgium;Italy
4	NCT05029921 (ClinicalTrials.gov)	December 10, 2021	30/8/2021	A Study of Ustekinumab(STELARA) in Chinese Participants With Moderately to Severely Active Crohn's D ...	A Phase 4, Single Arm, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Efficacy of ...	Crohn Disease	Drug: Ustekinumab	Janssen Research & Development, LLC	NULL	Recruiting	18 Years	N/A	All	180	Phase 4	China
5	NCT04629196 (ClinicalTrials.gov)	November 2021	10/11/2020	Induction Optimization With Stelara for Crohn's Disease	Induction Optimization With Stelara for Crohn's Disease	Crohn Disease	Drug: Ustekinumab	NYU Langone Health	NULL	Not yet recruiting	18 Years	70 Years	All	113	Phase 4	United States
6	EUCTR2020-004457-76-PL (EUCTR)	28/10/2021	15/09/2021	A Long-term Extension Study of Ustekinumabin Pediatric Participants with different medical condition ...	A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumabin Pediatric Cli ...	Paediatric conditions in - Moderately to Severely Active Crohn's Disease - Moderately to Severely Ac ...	Trade Name: STELARA ® Product Name: Ustekinumab Product Code: CNTO1275 INN or Proposed INN: Ustekinumab O ...	Janssen-Cilag International NV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 3	France;United States;Argentina;Poland;Turkey;Russian Federation;Japan
7	NCT05092269 (ClinicalTrials.gov)	October 18, 2021	13/10/2021	A Long-term Extension Study of Ustekinumab in Pediatric Participants	A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumabin Pediatric Cli ...	Crohn Disease;Colitis, Ulcerative;Arthritis, Psoriatic	Drug: Ustekinumab	Janssen Research & Development, LLC	NULL	Recruiting	2 Years	17 Years	All	151	Phase 3	United States;Belgium;France;Hungary;Poland
8	NCT04978493 (ClinicalTrials.gov)	October 4, 2021	26/7/2021	A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease	A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Ph ...	Crohn Disease	Drug: BI 706321;Drug: ustekinumab;Drug: Placebo	Boehringer Ingelheim	NULL	Recruiting	18 Years	75 Years	All	50	Phase 2	United States;Poland
9	NCT03712826 (ClinicalTrials.gov)	October 2021	16/8/2018	Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Bi ...	Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Bi ...	Crohn Disease	Drug: Anti-TNF Drug;Drug: Ustekinumab	Hospices Civils de Lyon	NULL	Not yet recruiting	18 Years	N/A	All	60	N/A	France
10	JPRN-jRCT2031200345	11/08/2021	05/02/2021	A Study of Ustekinumab in Pediatric Participants with Moderately to Severely Active Crohn's Disease	A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumabas Open-label Intravenou ...	Crohn Disease	-Ustekinumab Ustekinumabwill be administered intravenously in induction period and subcutaneously in ...	Nishikawa Kazuko	NULL	Recruiting	>= 2age old	< 18age old	Both	90	Phase 3	United States Of America;Belgium;Germany;Hungary;Poland;Russian Federation;United Kingdom Of Great B ...

First Previous1 2 3 4 5…18Next Last